Amebiasis News and Research

RSS

Amebiasis (Amoebiasis) is a term for disease caused by the protozoan parasite Entamoeba histolytica that primarily infects the human bowel, but can also affect other organs (most commonly the liver). Entamoeba histolytica can exist in two forms – as a short-lived motile trophozoite with the ability to invade different organ systems, and as a long-surviving cyst that is able to colonize a patient.

Entamoeba gingivalis linked to severe and recurrent periodontitis

For the first time, researchers from Charité - Universitätsmedizin Berlin have shown that a unicellular parasite commonly found in the mouth plays a role in both severe tissue inflammation and tissue destruction.

16 Apr 2020

UC San Diego establishes new Center For Anti-Parasitic Drug Discovery And Development

Neglected tropical diseases are a group of chronic and disabling parasitic infections that primarily affect poor and underserved communities.

14 Jun 2018

Antibiotic use makes immune cells less effective in fighting infections

Adding another reason for doctors to avoid the overuse of antibiotics, new research shows that a reduction in the variety of microbes in the gut interferes with the immune system's ability to fight off disease.

17 Aug 2017

RA drug effective against Entamoeba histolytica

Research by a collaborative group of scientists from UC San Diego School of Medicine, UC San Francisco and Wake Forest School of Medicine has led to identification of an existing drug that is effective against Entamoeba histolytica. This parasite causes amebic dysentery and liver abscesses and results in the death of more than 70,000 people worldwide each year.

21 May 2012

Auranofin effective against amoebas in lab and animal studies

A team of researchers from UCSF and UC San Diego has identified an approved arthritis drug that is effective against amoebas in lab and animal studies, suggesting it could offer a low-dose, low cost treatment for the amoebic infections that cause human dysentery throughout the world.

21 May 2012

FDA approves Impax's ANDA for generic Doryx 75 and 100mg tablets

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx® (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

29 Dec 2010